Clinical and Experimental Immunology

Scope

Clinical & Experimental Immunology has published research at the cutting edge of translational and clinical immunology since 1966. We are interested in studies that have the potential to transform our understanding of the immunopathology of human disease and/or change clinical practice. The journal is among the foremost journals in the field of translational and clinical immunology, attracting high-quality papers from across the world. Translation is viewed as a process of applying ideas, insights and discoveries generated through scientific studies to the treatment, prevention or diagnosis of human disease. Clinical immunology has evolved as a field to encompass the application of state-of-the-art technologies such as next-generation sequencing, metagenomics and high-dimensional phenotyping to understand the mechanisms that govern the outcomes of clinical trials. Journal articles are received by our dedicated Section Editors and cover basic and clinical investigations into the immunological basis of a wide range of human pathologies including autoimmunity, inflammatory diseases, primary and secondary immunodeficiencies, complement disorders, allergies, infectious diseases, cancer and transplantation rejection. Research that offers mechanistic insight is particularly encouraged. Studies that inform clinical practice and those that represent position papers on the classification, diagnosis or treatment of immunological disease are also welcomed. Any paper which does not fit into one of the sections described below will be assessed by our Editor-in-Chief. All papers with high relevance to translational immunology are welcome. Clinical & Experimental Immunology is part of the British Society for Immunology family of journals, including our sibling journal Immunotherapy Advances.